drugset / Trial / NCT06439563

Study to Evaluate the Efficacy and Safety of JP-1366 in the Prevention of NSAIDs-Induced Peptic Ulcers

NCT06439563

Phase 3 Recruiting 364 enrolled Onconic Therapeutics Inc.
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The sutdy aims to to demonstrate the non-inferiority of JP-1366 10 mg compared to Lanston Capsule 15 mg in preventing NSAIDs-induced peptic ulcers and to compare/evaluate the efficacy and safety of JP-1366 10 mg.

Timeline

Start
2024-10-22
Primary completion
2027-08
Completion
2027-12

Drugs

EvaluationDrugModalityDoseRoute
Subject JP-1366 Unknown 10 mg Oral
Comparator Lanston Unknown 15 mg Oral

Indications